RXII - RXi Pharmaceuticals Corporation

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

RXi Pharmaceuticals Corporation

257 Simarano Drive
Suite 101
Marlborough, MA 01752
United States
508-767-3861
http://www.rxipharma.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees15

Key Executives

NameTitlePayExercisedYear Born
Dr. Geert CauwenberghPres, CEO, CFO & Director611.95kN/A1954
Dr. Gerrit Dispersyn Dr. Med. ScChief Devel. OfficerN/AN/A1975
Karen BulockVP of ResearchN/AN/AN/A
Ms. Caitlin KontulisDirector of Fin. & Sec.N/AN/A1986
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

RXi Pharmaceuticals Corporation, a biotechnology company, focuses on discovering and developing immuno-oncology therapeutics to treat cancer. The company's lead product candidate is RXI-109, an sd-rxRNA that reduces the expression of connective tissue growth factor, a critical regulator of several biological pathways involved in fibrosis, including scar formation in the skin and eye. The company also develops Samcyprone, a topical formulation of the small molecule diphenylcyclopropenone that is in a Phase IIa clinical trial for the clearance of common warts; RXI-231, an sd-rxRNA compound targeting tyrosinase, as a cosmetic ingredient that may enhance the appearance of uneven skin tone and pigmentation; and RXI-185, an sd-rxRNA compound targeting collagenase, as a cosmetic ingredient that may improve the appearance of wrinkles or skin laxity. In addition, it develops RXI-109, a Phase I/II clinical trial that reduces the progression of retinal scarring. RXi Pharmaceuticals Corporation has collaborations with Center for Cancer Immune Therapy; Gustave Roussy; Medigene AG; and PCI Biotech. The company was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.

Corporate Governance

RXi Pharmaceuticals Corporation’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.